Rayner
Matt Clayton has extensive work experience as a mechanical development engineer. Matt is currently working at Rayner as a Senior Mechanical Development Engineer since October 2019. In this role, they are responsible for driving the mechanical and device design forward, conducting mechanical and optical tests, designing test equipment, and integrating various systems. Matt also manages risk and provides technical support.
Prior to joining Rayner, Matt worked at Eschmann Equipment as a Senior Mechanical Development Engineer from January 2012 to September 2018. Here, they led major NPD projects, including Electro Mechanical Operating tables for the US market. Matt was responsible for the overall mechanical design, integration of electrical components, prototype builds, and supporting documentation. Before that, from June 2006 to December 2011, they worked as a Mechanical Development Engineer at Eschmann Equipment.
Matt's earlier work experience includes working at LEC Refrigeration as a Project Design Engineer from July 2000 to May 2006. Here, they worked on NPD and product improvement projects for refrigerated commercial product ranges and was responsible for product design from concept development to production. Prior to that, they worked as a Design Draughtsman at LEC Refrigeration from April 1998 to July 2000, supporting bespoke commercial refrigerated products.
Overall, Matt Clayton has a strong background in mechanical development engineering and has worked on various projects throughout their career.
Matt Clayton attended Kingston University from 1996 to 1998, where they pursued a Bachelor of Science degree in Automotive Systems Engineering.
This person is not in any offices
Rayner
5 followers
Rayner designs and manufactures intraocular lenses and proprietary injection devices for use in cataract surgery. When Sir Harold Ridley designed the world’s first IOL in 1949, he chose Rayner to manufacture this ground-breaking invention.With more than 65 years of continuous growth and experience, we remain at the forefront of innovation. Weare focused on providing the best IOLs for clinicians and patients and are driven by science to improve patient outcomes and safety.Primary IOLs Our FDA-approved C-flex aspheric (aberration-neutral) monofocal IOL, as well as our toric and multifocal IOL families are now complemented by the RayOne fully preloaded monofocal IOL injection system. Supplementary IOLsDesigned to be implanted in the ciliary sulcus, Rayner Sulcoflex Pseudophakic Supplementary IOLs are available as aspheric, toric, multifocal and multifocal lenses, and offer a reversible solution for correcting residual post-operative refractive errors following the implantation of a conventional IOL in the capsular bag.OVDsOur Ophteis range offers a full spectrum of OVDs from dispersive to cohesive, enabling surgeons to select the OVD best suited to each specific cataract procedure. Ophteis FR Pro with sorbitol -- designed to deliver a new level of corneal endothelial protection from phaco induced trauma -- is the flagship product of Rayner’s ‘Ophteis’ OVD suite. PharmaceuticalsAlthough the intraocular lens plays a leading role in the visual outcomes of cataract and refractive surgery, the pharmaceuticals that manage the tear film and inflammation are critical to the end result. For that reason, Rayner recently acquired the business of Moorfields Pharmaceuticals. The acquisition will enable us to offer an even wider range of ophthalmic tools that aid and streamline the surgical process whilst remaining focused on the visual outcome for the patient.Rayner markets its IOL portfolio and related products worldwide through a network of distributors in over 80 countries with direct markets in UK, Germany & Austria, the United States of America, Italy and Spain. We have the world’s longest commercial history of IOL design and manufacturing and have worked with cataract surgeons for longer than anyone else.In 2016, Rayner transferred its global headquarters to a brand new state of the art manufacturing plant, which has dramatically increased the company’s production capacity.